Compare Novavax Inc (NVAX) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Ryanair Holdings plc — how do they compare? Novavax Inc trades at $12.04 (market cap $1.82B), while Ryanair Holdings plc trades at $52.86 (market cap $27.11B). The key difference: Ryanair Holdings plc is far larger — about 14.9× Novavax Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Ryanair Holdings plc for 72 Days on average.
| NVAX | RYAAY | |
|---|---|---|
Market Cap | $1.82B | $27.11B |
Volume | 6,198,505 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $12.56 | $73.82 |
52-Week Low | $6.22 | $51.95 |
Typical Hold Time | 59 Days | 72 Days |
Enterprise Value | $1.39B | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
RYAAY trades at $53.1, down 5.18% on the day, reflecting a bearish technical signal amid mixed earnings performance. The company maintains strong profitability with a 12.13% net income margin and 22.41% ROE, while valuation metrics like a P/E of 13.43 appear attractive. Recent news highlights CEO commentary on Boeing MAX 10 certification delays and concerns over rising fuel costs impacting future airfares.
The stock presents a value opportunity given its low valuation multiples and robust cash flow generation, but faces near-term headwinds from volatile fuel prices and a lowered FY27 traffic outlook. Analyst consensus remains moderately bullish, though technical indicators suggest caution. Key risks include oil price sensitivity and competitive pressures in the European airline sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
